{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:19:43Z","timestamp":1761311983071,"version":"build-2065373602"},"reference-count":112,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The aim of this review is to appraise the data from available randomized clinical trials (RCT) regarding the possible combinations of neuroleptic and non-antipsychotic treatment which could enhance antipsychotic therapy efficacy whilst simultaneously addressing somatic symptoms in individuals with schizophrenia. A systematic search of the PubMed database up to February 2022 was conducted. Inclusion criteria: randomized controlled trials using augmentation therapy in chronic schizophrenia in adults, written in English, and only studies with psychometric assessments of schizophrenia were incorporated. Exclusion criteria: non-clinical, first episode of schizophrenia, patients on medication other than antipsychotics augmented, and not adjunctive therapy. Overall, 37 studies of 1931 patients with schizophrenia who received a combination of antipsychotic medication with other drugs were selected. A statistically significant reduction of negative and positive symptoms of schizophrenia, measured with the PANSS scale, when using a combination of antipsychotic treatment along with aspirin, simvastatin, N-acetylcysteine, or pioglitazone was found. A combination of antipsychotic medication with aspirin, simvastatin, N-acetylcysteine, or pioglitazone seems to be effective in the reduction of symptoms of schizophrenia in adults, but long-term studies are required to confirm this effect.<\/jats:p>","DOI":"10.3390\/jcm12124012","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T02:00:45Z","timestamp":1686621645000},"page":"4012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia\u2014A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7880-287X","authenticated-orcid":false,"given":"Wiktor","family":"Dr\u00f3\u017cd\u017c","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Wici\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-342X","authenticated-orcid":false,"given":"Anna Maria","family":"Szota","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Szambelan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Radajewska","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Pop\u0142awski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Ludwig Rydygier Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toru\u0144, Curie Sk\u0142odowskiej Street 9, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104257","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014An Overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses","volume":"21","author":"Leichsenring","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/schbul\/sbw028","article-title":"Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span","volume":"42","author":"Dieset","year":"2016","journal-title":"Schizophr. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00125-021-05609-x","article-title":"Prevalence of type 2 diabetes in psychiatric disorders: An umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews","volume":"65","author":"Lindekilde","year":"2021","journal-title":"Diabetologia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Oud, M.J.T., and Jong, B.M.-D. (2009). Somatic diseases in patients with schizophrenia in general practice: Their prevalence and health care. BMC Fam. Pr., 10.","DOI":"10.1186\/1471-2296-10-32"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.12740\/PP\/37845","article-title":"The European studies on mortality in schizophrenia","volume":"49","author":"Gondek","year":"2015","journal-title":"Psychiatr. Polska"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess Early Mortality in Schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"ref_11","first-page":"151","article-title":"Assessment of Mortality Rate in 10 Years and the Associated Risk Factors in Schizophrenia","volume":"32","author":"Yasar","year":"2020","journal-title":"Turk. Psikiyatri. Derg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-0827-5","article-title":"Drug repositioning for psychiatric and neurological disorders through a network medicine approach","volume":"10","author":"Dias","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21116","DOI":"10.1038\/s41598-022-24980-2","article-title":"DrugRepo: A novel approach to repurposing drugs based on chemical and genomic features","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sadeghi, H.M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., and Abdollahi, M. (2021). Drug Repurposing for the Management of Depression: Where Do We Stand Currently?. Life, 11.","DOI":"10.3390\/life11080774"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/wps.20481","article-title":"The promise and challenges of drug repurposing in psychiatry","volume":"17","author":"Fava","year":"2018","journal-title":"World Psychiatry"},{"key":"ref_16","first-page":"6378137","article-title":"Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr. Res. Treat."},{"key":"ref_17","first-page":"CD003468","article-title":"Amantadine in Parkinson\u2019s disease","volume":"1","author":"Crosby","year":"2003","journal-title":"Cochrane Database Systemat. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: A prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jclinepi.2014.12.017","article-title":"Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions","volume":"68","author":"Halladay","year":"2015","journal-title":"J. Clin. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102213","DOI":"10.1016\/j.cpr.2022.102213","article-title":"Virtual reality in the diagnostic and therapy for mental disorders: A systematic review","volume":"98","author":"Wiebe","year":"2022","journal-title":"Clin. Psychol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/schbul\/sbab010","article-title":"Simvastatin Augmentation for Patients with Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial","volume":"47","author":"Sommer","year":"2021","journal-title":"Schizophr. Bull."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.psychres.2018.02.018","article-title":"Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications","volume":"262","author":"Shen","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.psychres.2014.06.039","article-title":"Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial","volume":"219","author":"Ghanizadeh","year":"2014","journal-title":"Psychiatry Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0000000000000159","article-title":"Simvastatin adjunct therapy for negative symptoms of schizophrenia: A randomized double-blind placebo-controlled trial","volume":"32","author":"Abbasi","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2045125313511487","article-title":"Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: Pilot study","volume":"4","author":"Chaudhry","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_29","first-page":"1269","article-title":"Effects of Atorvastatin on negative sign in chronic schizophrenia: A double blind clinical trial","volume":"14","author":"Sayyah","year":"2015","journal-title":"Iran J. Pharm. Res."},{"key":"ref_30","first-page":"S355","article-title":"Efficacy of Ondansetron and Simvastatin on Cognition and Negative Symptoms in Established Schizophrenia","volume":"Volume 39","author":"Deakin","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia\u2014A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","article-title":"N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients with Chronic Schizophrenia: A randomized, double-blind, placebo-controlled study","volume":"36","author":"Farokhnia","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pnpbp.2017.11.001","article-title":"Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial","volume":"82","author":"Sepehrmanesh","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.2517","article-title":"The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: A double-blind and placebo-controlled trial","volume":"31","author":"Iranpour","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis","volume":"49","author":"Koola","year":"2019","journal-title":"Psychol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0920-9964(00)00088-8","article-title":"Estrogen\u2014A potential treatment for schizophrenia","volume":"48","author":"Kulkarni","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/archpsyc.65.8.955","article-title":"Estrogen in Severe Mental Illness: A potential new treatment approach","volume":"65","author":"Kulkarni","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.schres.2010.10.009","article-title":"Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?","volume":"125","author":"Kulkarni","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0278-5846(03)00161-1","article-title":"Adjunctive estrogen treatment in women with chronic schizophrenia: A double-blind, randomized, and placebo-controlled trial","volume":"27","author":"Akhondzadeh","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(03)00082-3","article-title":"Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: A double-blind study","volume":"66","author":"Marques","year":"2004","journal-title":"Schizophr. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3371\/CSRP.GHFA.01062013","article-title":"Combination of Estrogen and Antipsychotics in the Treatment of Women with Chronic Schizophrenia: A double-blind, randomized, placebo-controlled clinical trial","volume":"6","author":"Ghafari","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/2008-2231-22-55","article-title":"Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: A randomized double-blind and placebo controlled trial","volume":"22","author":"Kianimehr","year":"2014","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_43","first-page":"337","article-title":"A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia","volume":"53","author":"Khosravi","year":"2015","journal-title":"Acta MEDICA Iran."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","article-title":"Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial","volume":"73","author":"Kulkarni","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/schbul\/sbv149","article-title":"Raloxifene as an Adjunctive Treatment for Postmenopausal Women with Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial","volume":"42","author":"Usall","year":"2015","journal-title":"Schizophr. Bull."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.4088\/JCP.15m10498","article-title":"Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women with Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial","volume":"78","author":"Weiser","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","article-title":"Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: A meta-analysis","volume":"234","author":"Kishi","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"Fernandes","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"MEM-MD-29 Study Group. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4306\/pi.2012.9.2.166","article-title":"Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study","volume":"9","author":"Lee","year":"2012","journal-title":"Psychiatry Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","article-title":"Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized, double-blind, placebo-controlled study","volume":"33","author":"Rezaei","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/2277-9175.166148","article-title":"The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial","volume":"4","author":"Omranifard","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_53","first-page":"696","article-title":"Memantine Enhances the Effect of Olanzapine in Patients with Schizophrenia: A Randomized, Placebo-Controlled Study","volume":"54","author":"Fakhri","year":"2016","journal-title":"Acta MEDICA Iran."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1017\/S0033291716000398","article-title":"Memantine augmentation in clozapine-refractory schizophrenia: A randomized, double-blind, placebo-controlled crossover study","volume":"46","author":"Veerman","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.psychres.2016.09.028","article-title":"Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial","volume":"247","author":"Mazinani","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","article-title":"Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials","volume":"113","author":"Zheng","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.schres.2008.08.004","article-title":"Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial","volume":"107","author":"Akhondzadeh","year":"2009","journal-title":"Schizophr. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/0269881118798608","article-title":"Ondansetron-a promising adjunctive treatment for persistent schizophrenia","volume":"32","author":"Kulkarni","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_59","first-page":"14","article-title":"Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial","volume":"42","author":"Samadi","year":"2017","journal-title":"Iran. J. Med. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","article-title":"Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study","volume":"88","author":"Zhang","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/acps.12799","article-title":"The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia","volume":"136","author":"Fan","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"ref_63","first-page":"812","article-title":"Aspirin Inhibits Vasopressin-Induced Hypothalamic-Pituitary-Adrenal Activity in Normal Humans1","volume":"82","author":"Nye","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03191015","article-title":"Effect of aminophylline on aspirin penetration into the central nervous system in rats","volume":"33","author":"Tomic","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00702-004-0231-y","article-title":"Prostaglandin-mediated control of rat brain kynurenic acid synthesis\u2013opposite actions by COX-1 and COX-2 isoforms","volume":"112","author":"Schwieler","year":"2004","journal-title":"J. Neural Transm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/schbul\/sbaa013","article-title":"Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients with Psychotic Disorders: A Population-Based Cohort Study","volume":"46","author":"Chang","year":"2020","journal-title":"Schizophr. Bull."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1515\/pteridines-2020-0028","article-title":"Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder","volume":"32","author":"Postolache","year":"2021","journal-title":"Pteridines"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10753-009-9178-3","article-title":"Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals","volume":"33","author":"Rosendo","year":"2010","journal-title":"Inflammation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/CIA.S40405","article-title":"Atorvastatin attenuates the production of IL-1\u03b2, IL-6, and TNF-\u03b1 in the hippocampus of an amyloid \u03b21-42-induced rat model of Alzheimer\u2019s disease","volume":"8","author":"Li","year":"2013","journal-title":"Clin. Interv. Aging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00011-011-0323-8","article-title":"Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages","volume":"60","author":"Palacio","year":"2011","journal-title":"Inflamm. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2021.09.006","article-title":"The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study","volume":"238","author":"Chesney","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008571-200303000-00006","article-title":"The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement","volume":"13","author":"Steijns","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2015.09.021","article-title":"The effects of N -Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study","volume":"156","author":"Froeliger","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/1516-4446-2019-0753","article-title":"N-acetylcysteine as an adjunctive treatment for smoking cessation: A randomized clinical trial","volume":"42","author":"Machado","year":"2020","journal-title":"Rev. Bras. De Psiquiatr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: A new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","first-page":"6098961","article-title":"Immunomodulatory Effects of 17\u03b2-Estradiol on Epithelial Cells during Bacterial Infections","volume":"2018","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S2215-0366(21)00383-7","article-title":"Towards better care for women with schizophrenia-spectrum disorders","volume":"9","author":"Brand","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"ref_78","first-page":"670","article-title":"Hyperprolactinemia associated with psychiatric disorders","volume":"80","author":"Rizzo","year":"2020","journal-title":"Medicina"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1574886317666220216101106","article-title":"Consequences of Antipsychotic Medications on Mental Health","volume":"17","author":"Bukhari","year":"2021","journal-title":"Curr. Drug Saf."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpsychires.2021.08.022","article-title":"Levels of prolactin and testosterone and associated sexual dysfunction and breast abnormalities in men with schizophrenia treated with antipsychotic medications","volume":"143","author":"Redman","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"ref_81","first-page":"33","article-title":"The effects of estrogen and hormone replacement therapy on platelet activity: A review","volume":"12","author":"Hashemzadeh","year":"2022","journal-title":"Am. J. Blood Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697137.2020.1851183","article-title":"Hormone replacement therapy\u2013where are we now?","volume":"24","author":"Langer","year":"2021","journal-title":"Climacteric"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Farkas, S., Szab\u00f3, A., Hegyi, A.E., T\u00f6r\u00f6k, B., Fazekas, C.L., Ernszt, D., Kov\u00e1cs, T., and Zelena, D. (2022). Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040861"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/13697137.2014.929106","article-title":"Impact of smoking on estrogenic efficacy","volume":"18","author":"Ruan","year":"2014","journal-title":"Climacteric"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00213-016-4318-6","article-title":"Targeting glutamate to treat schizophrenia: Lessons from recent clinical studies","volume":"233","author":"Beck","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/ajp.154.8.1171a","article-title":"Augmentation of clozapine therapy with ondansetron","volume":"154","author":"Briskin","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92851-R","article-title":"Ondansetron in treatment of schizophrenia","volume":"337","author":"White","year":"1991","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1176\/appi.ajp.162.2.386","article-title":"Improved P50 Auditory Gating with Ondansetron in Medicated Schizophrenia Patients","volume":"162","author":"Adler","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-020-00135-y","article-title":"Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia","volume":"7","author":"Lintunen","year":"2021","journal-title":"Schizophrenia"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"B\u00fcki, A., Kekesi, G., Horvath, G., and V\u00e9csei, L. (2021). A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810016"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12640-017-9781-2","article-title":"Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain\u2014Its Possible Clinical Applications","volume":"32","author":"Zakrocka","year":"2017","journal-title":"Neurotox. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0269881115625496","article-title":"Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes","volume":"30","author":"Mayfield","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wici\u0144ski, M., Socha, M., Malinowski, B., W\u00f3dkiewicz, E., Walczak, M., G\u00f3rski, K., S\u0142upski, M., and Pawlak-Osi\u0144ska, K. (2019). Liraglutide and its Neuroprotective Properties\u2014Focus on Possible Biochemical Mechanisms in Alzheimer\u2019s Disease and Cerebral Ischemic Events. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051050"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuroscience.2014.09.064","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia","volume":"281","author":"Briyal","year":"2014","journal-title":"Neuroscience"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients with Schizophrenia Spectrum Disorder: A Randomized Clinical Trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.psyneuen.2016.11.036","article-title":"Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis","volume":"77","author":"Zorn","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e021444","DOI":"10.1161\/JAHA.121.021444","article-title":"Cardiovascular Risk for Patients with and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder","volume":"11","author":"Rossom","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_105","first-page":"370","article-title":"Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications","volume":"14","author":"Tek","year":"2016","journal-title":"Focus (Am. Psychiatr. Publ.)"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"pyv121","DOI":"10.1093\/ijnp\/pyv121","article-title":"A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project","volume":"19","author":"Bioque","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.encep.2008.03.007","article-title":"Enqu\u00eate de pratiques de prescription des antipsychotiques dans 13 centres hospitaliers du r\u00e9seau PIC [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]","volume":"35","author":"Bret","year":"2009","journal-title":"Encephale"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.pharep.2014.02.024","article-title":"The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland","volume":"66","author":"Jaracz","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ajp.2019.02.005","article-title":"Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia","volume":"40","author":"Hatta","year":"2019","journal-title":"Asian J. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients with Schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpsychires.2021.09.018","article-title":"Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials","volume":"143","author":"Bartoli","year":"2021","journal-title":"J. Psychiatr. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/12\/4012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:32Z","timestamp":1760126012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/12\/4012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":112,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12124012"],"URL":"https:\/\/doi.org\/10.3390\/jcm12124012","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}